• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Merrimack Pharmaceuticals Inc.

    8/4/22 4:28:38 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MACK alert in real time by email
    SC 13G 1 p7213ga.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

    (Name of Issuer)

    Merrimack Pharmaceuticals, Inc.

    (Title of Class of Securities)

    Common Stock, $0.01 Par Value Per Share

    (CUSIP Number)

    590328209

    (Date of Event Which Requires Filing of this Statement)

    August 3, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).


    CUSIP No. 590328209
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              900,487 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       900,487 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    900,487 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 6.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. 590328209
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              900,487 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       900,487 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    900,487 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 6.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. 590328209
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              494 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       494 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    494 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 590328209
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              900,981 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       900,981 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    900,981 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 6.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:

    Merrimack Pharmaceuticals, Inc.

    Item 1(b) Address of issuer's principal executive offices:

    One Broadway, 14th Floor, Cambridge, MA 02142

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, $0.01 par value per
    share (“Shares”), of the Issuer held by certain investment funds it manages;
    (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with
    respect to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Cubist Systematic Strategies.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of
    which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they
    have agreed to file this Schedule 13G jointly in accordance with the
    provisions of Rule 13d-1(k) of the Act.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc.
    is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Mr. Cohen is a United States citizen.

    2(d) Title of class of securities:

    Common Stock, $0.01 Par Value Per Share

    2(e) CUSIP Number:

    590328209

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on August 3, 2022:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 900,487
    (b) Percent of class: 6.7%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 900,487 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 900,487

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 900,487
    (b) Percent of class: 6.7%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 900,487 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 900,487

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 494
    (b) Percent of class: <0.1%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 494 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 494

    4. Steven A. Cohen
    (a) Amount beneficially owned: 900,981
    (b) Percent of class: 6.7%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 900,981 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 900,981

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment
    management agreement, Point72 Asset Management maintains investment and voting
    power with respect to the securities held by certain investment funds it manages.
    Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.
    Pursuant to an investment management agreement, Cubist Systematic Strategies maintains
    investment and voting power with respect to the securities held by certain investment
    funds it manages. Mr. Cohen controls each of Point72 Asset Management, Point72
    Capital Advisors Inc., and Cubist Systematic Strategies. By reason of the provisions of
    Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of (i) Point72 Asset
    Management, Point72 Capital Advisors Inc., and Mr. Cohen may be deemed to beneficially
    own 900,487 Shares (constituting approximately 6.7% of the Shares outstanding) and
    (ii) Cubist Systematic Strategies and Mr. Cohen may be deemed to beneficially own
    494 Shares (constituting <0.1% of the Shares outstanding). Each of Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen
    disclaims beneficial ownership of any of the securities covered by this statement.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [  ].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, other than activities
    solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.


    Dated: August 4, 2022


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $MACK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MACK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr

      5/10/24 4:30:00 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua

      5/9/24 7:30:00 AM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andersen Eric bought $651,754 worth of shares (49,550 units at $13.15) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/28/23 4:05:12 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $1,298,472 worth of shares (101,050 units at $12.85) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/11/23 4:05:08 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $3,750 worth of shares (300 units at $12.50) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      11/20/23 6:59:37 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andersen Eric bought $651,754 worth of shares (49,550 units at $13.15) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/28/23 4:05:12 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $1,298,472 worth of shares (101,050 units at $12.85) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      12/11/23 4:05:08 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Eric bought $3,750 worth of shares (300 units at $12.50) (SEC Form 4)

      4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

      11/20/23 6:59:37 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Financials

    Live finance-specific insights

    See more
    • Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr

      5/10/24 4:30:00 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

      Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua

      5/9/24 7:30:00 AM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

      Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024. Under the Plan of Dissolution, Merrimack intends to issue an initial liquidating cash dividend to its stockholders, subject to receipt of stockholder approval of the Plan of Dissolution. The Company currently estimates a cash divid

      4/30/24 5:15:00 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • 180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

      MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors ("Board") effective June 15, 2021. Russell Ray was formerly Managing Director and Co-Head of Global Health Care at Credit Suisse First Boston Corporation where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco focused on providing corporate finance and M&A adv

      5/28/21 8:00:00 AM ET
      $MACK
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    SEC Filings

    See more
    • SEC Form 15-12G filed by Merrimack Pharmaceuticals Inc.

      15-12G - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

      5/20/24 4:05:28 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Merrimack Pharmaceuticals Inc.

      10-Q - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

      5/15/24 4:15:28 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Merrimack Pharmaceuticals Inc.

      25 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

      5/10/24 4:45:35 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

      SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

      2/14/24 4:20:24 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

      SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

      1/25/24 4:05:32 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

      SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

      12/13/23 4:05:25 PM ET
      $MACK
      Biotechnology: Pharmaceutical Preparations
      Health Care